FY2025 EPS Estimates for Genmab A/S Boosted by HC Wainwright

Genmab A/S (NASDAQ:GMAB - Free Report) - Stock analysts at HC Wainwright raised their FY2025 earnings per share (EPS) estimates for Genmab A/S in a report issued on Thursday, April 24th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of $1.58 per share for the year, up from their prior forecast of $1.48. HC Wainwright currently has a "Buy" rating and a $37.00 price objective on the stock. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share. HC Wainwright also issued estimates for Genmab A/S's Q4 2025 earnings at $0.47 EPS, Q1 2026 earnings at $0.29 EPS, Q2 2026 earnings at $0.53 EPS, Q3 2026 earnings at $0.51 EPS and Q4 2026 earnings at $0.52 EPS.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%.

A number of other research analysts have also recently issued reports on the company. BNP Paribas raised Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 11th. Leerink Partners raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target for the company in a report on Thursday, February 13th. Sanford C. Bernstein cut shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday, April 1st. Truist Financial cut their target price on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. Finally, Leerink Partnrs upgraded Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $39.17.

Genmab A/S Trading Up 0.2 %

Shares of GMAB opened at $20.59 on Monday. The stock has a 50 day simple moving average of $20.47 and a 200-day simple moving average of $21.02. The stock has a market cap of $13.63 billion, a PE ratio of 11.83, a PEG ratio of 2.65 and a beta of 1.07. Genmab A/S has a 1 year low of $17.24 and a 1 year high of $30.41.

Institutional Investors Weigh In On Genmab A/S

A number of institutional investors and hedge funds have recently modified their holdings of GMAB. EverSource Wealth Advisors LLC lifted its stake in shares of Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after purchasing an additional 939 shares during the period. Lindbrook Capital LLC grew its position in shares of Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after buying an additional 950 shares during the period. GAMMA Investing LLC increased its stake in shares of Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after acquiring an additional 1,051 shares during the last quarter. Barclays PLC raised its position in shares of Genmab A/S by 1,072.8% in the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after acquiring an additional 2,285 shares during the period. Finally, Cromwell Holdings LLC boosted its stake in Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock worth $60,000 after acquiring an additional 2,496 shares during the last quarter. 7.07% of the stock is owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.